Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

DUBLIN, October 28, 2011 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to September 30, 2011.

Financial Highlights Q3 2011(1) Product sales $1,018 million +28% Total revenues $1,086 million +24% Non GAAP operating income $341 million +15% US GAAP operating income $255 million +64% Non GAAP diluted earnings per ADS $1.28 +10% US GAAP diluted earnings per ADS $1.02 +96% Non GAAP cash generation $296 million +9% Non GAAP free cash flow $138 million +56% US GAAP net cash provided by operating activities $179 million +26%

(1)    Percentages compare to equivalent period in 2010.

The Non GAAP financial measures included within this release are explained on page 24, and are reconciled to the most directly comparable financial measures prepared in accordance with US GAAP on pages 19 - 23.

Angus Russell, Chief Executive Officer, commented:

"Shire has delivered another strong set of quarterly results. Total product sales were up 28% to $1,018 million, with our newly acquired regenerative medicine product, DERMAGRAFT for Diabetic Foot Ulcers, contributing sales of $50 million in the quarter. We're on track to deliver significant 2011 earnings growth.

Sales of our rare disease treatments were very strong: with VPRIV up 31% and REPLAGAL up 40% versus the same quarter in 2010. FIRAZYR, our self-administered treatment for acute attacks of Hereditary Angioedema, was approved by the FDA in August and launched just a few weeks ago; initial demand from patients has been positive. This week we have also initiated a rolling Biologics License Application for REPLAGAL in the US, designated Fast Track by the FDA.

The US ADHD market continues to grow and with a strong 'back to school' season, our portfolio of treatments has gained sha
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... December 17, 2014 Achim Noack has ... for Stoller Group. In this position, Noack will assist ... administrative matters, develop marketing strategy and supervise global marketing ... , “Achim has tremendous knowledge and experience in the ... Group. “His experience and innovative thinking will be a ...
(Date:12/17/2014)... Xeno Diagnostics has again received ... recent COLA inspection. Xeno has met all criteria ... accreditation organization. Accreditation is earned only by laboratories ... operations, demonstrate continued accuracy in the performance of ... survey. , While the Laboratory Excellence ...
(Date:12/17/2014)... , Dec. 17, 2014  United Therapeutics Corporation (NASDAQ: ... promotions as well as changes to Martine Rothblatt ... Promotions United Therapeutics announced the promotion ... Co-Chief Executive Officer and David Zaccardelli , Pharm.D. ... connection with these promotions, Dr. Rothblatt,s title will change ...
(Date:12/15/2014)... 2014 METTLER TOLEDO is pleased ... ParticleView V19 with PVM technology , is ... vision and measurement tool continuously captures high-resolution images ... V19 then automatically prepares a report pairing the ... and concentration changes. This compelling blend of high ...
Breaking Biology Technology:Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... Sales in the Third Quarter up by 7.2% to EUR268.0m, ... Third Quarter of 2008,From EUR7.4m to EUR16.5m, - Sales ... Axel Herberg Confirms the Outlook for 2008, Gerresheimer AG ... the third quarter of 2008. Overall, sales by the,globally operating ...
... October 2008] Recent research from the Swedish medical university ... stem cells discoveries that contradict previous findings. The ... show amongst other things, that hair follicle stem cells ... tissue. , "The stem cells don,t behave ...
... Based on its recent,analysis of the bone healing ... the 2008 North American Frost & Sullivan Award ... Extender and Substitute,scaffold. InQu represents the first commercial ... platform technology., Although spinal fusions and other ...
Cached Biology Technology:Gerresheimer Substantially Increases Quarterly Operating Profit 2Gerresheimer Substantially Increases Quarterly Operating Profit 3Gerresheimer Substantially Increases Quarterly Operating Profit 4Gerresheimer Substantially Increases Quarterly Operating Profit 5Frost & Sullivan Acknowledges ISTO Technologies' Role in Developing Advanced Biologic Products for Bone Healing 2Frost & Sullivan Acknowledges ISTO Technologies' Role in Developing Advanced Biologic Products for Bone Healing 3Frost & Sullivan Acknowledges ISTO Technologies' Role in Developing Advanced Biologic Products for Bone Healing 4
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... Region 2015-2019"  report to their offering. ... is advances in technology. With continuous advances in ... to the latest standard that meets the needs ...
(Date:12/10/2014)... You,ve been here before: you desperately need to ... password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital ... finally put an end to the frustration that comes with ... 1U leverages a user,s smartphone to acquire his or her ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... N.C. By altering the genetic makeup of normally ... cells capable of generating and passing electrical current. ... treating diseases of the nervous system or the heart, ... to communicate with adjacent cells in order to function ...
... gene therapy into an arterial wall effectively protects the ... The promising results, published July 19 in the journal ... In atherosclerosis, fatty lesions called plaques form ... narrows arteries, thereby restricting blood flow and causing chest ...
... and Providence cities scattered across the eastern half ... all have coal-fired power plants. A new study from ... is among the first to investigate mercury deposits in ... The study, which appears in the July 2011 issue ...
Cached Biology News:Engineering excitable cells for studies of bioelectricity and cell therapy 2Engineering excitable cells for studies of bioelectricity and cell therapy 3Gene therapy delivered once to blood vessel wall protects against atherosclerosis in rabbit studies 2Gene therapy delivered once to blood vessel wall protects against atherosclerosis in rabbit studies 3Gene therapy delivered once to blood vessel wall protects against atherosclerosis in rabbit studies 4Soil samples reveal urban mercury footprints 2
...
... R&D Systems Cell and Tissue Staining Kits ... a broad range of histological and cytological ... primary IgG antibodies manufactured by either R&D ... is based on the formation of the ...
... Purification Protocols covers a wide range of ... and experienced researchers in all areas of ... from the books preface illustrates just how ... research library., The chapters introduce the theoretical ...
... The lower cost and reduced space ... make reference standard DNA analysis technology ... used with any of SEQUENOM's applications ... Genotyping (iPLEXTM Gold) , Gene Expression ...
Biology Products: